Factors associated with delay to medical recognition in two Canadian multiple sclerosis cohorts

Journal of the Neurological Sciences

Volumn 292, Issue 1-2, 2010, Pages 57-62

  Kingwell, Elaine ^a   Leung, Alexander L ^a   Roger, Elaine ^b   Duquette, Pierre ^b   Rieckmann, Peter ^a   Tremlett, Helen ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NOTRE DAME HOSPITAL   (Canada)

Author keywords

Age at onset; Cohort studies; Diagnostic delay; Epidemiology; Multiple sclerosis; Referral delay; Sex factors; Time factors

Indexed keywords

ADULT; ARTICLE; CANADA; CLINICAL ARTICLE; COHORT ANALYSIS; DATA BASE; DELAYED DIAGNOSIS; DISABILITY; DISEASE COURSE; FEMALE; GEOGRAPHY; HUMAN; MALE; MULTIPLE SCLEROSIS; OUTPATIENT DEPARTMENT; PATIENT REFERRAL; POPULATION; PRIORITY JOURNAL; RELAPSE; STRATIFICATION; SYMPTOM;

ADOLESCENT; ADULT; AGE FACTORS; AGE OF ONSET; CANADA; COHORT STUDIES; DISEASE PROGRESSION; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PHYSICIAN'S PRACTICE PATTERNS; PROGNOSIS; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SEX FACTORS; STATISTICS, NONPARAMETRIC;

EID: 77950092071     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2010.02.007     Document Type: Article

References (40)

1. Frohman E.M., Havrdova E., Lublin F., Barkhof F., Achiron A., Sharief M.K., et al. Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch. Neurol. 63 (2006) 614-619
2. National Clinical Advisory Board of the National Multiple Sclerosis Society. Disease Management Consensus Statement. 2007: Available from: http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-a bout-ms/treatments/index.aspx (accessed 22nd Jan 2010).
3. Pittock S.J., Weinshenker B.G., Noseworthy J.H., Lucchinetti C.F., Keegan M., Wingerchuk D.M., et al. Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch. Neurol. 63 (2006) 611-614
4. Jacobs L.D., Beck R.W., Simon J.H., Kinkel R.P., Brownscheidle C.M., Murray T.J., et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N. Engl. J. Med. 343 (2000) 898-904
5. Comi G., Filippi M., Barkhof F., Durelli L., Edan G., Fernandez O., et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357 (2001) 1576-1582
6. Johnson K.P., Brooks B.R., Ford C.C., Goodman A.D., Lisak R.P., Myers L.W., et al. Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial. Mult. Scler. 9 (2003) 585-591
7. Kinkel R.P., Kollman C., O'Connor P., Murray T.J., Simon J., Arnold D., et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 66 (2006) 678-684
8. Kappos L., Freedman M.S., Polman C.H., Edan G., Hartung H.P., Miller D.H., et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 370 (2007) 389-397
9. Poser C.M., Benedikz J., and Hibberd P.L. The epidemiology of multiple sclerosis: the Iceland model. Onset-adjusted prevalence rate and other methodological considerations. J. Neurol. Sci. 111 (1992) 143-152
10. Koch-Henriksen N. The Danish Multiple Sclerosis Registry: a 50-year follow-up. Mult. Scler. 5 (1999) 293-296
11. Celius E.G., and Vandvik B. Multiple sclerosis in Oslo, Norway: prevalence on 1 January 1995 and incidence over a 25-year period. Eur. J. Neurol. 8 (2001) 463-469
12. Barnett M.H., Williams D.B., Day S., Macaskill P., and McLeod J.G. Progressive increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: a 35-year study. J. Neurol. Sci. 213 (2003) 1-6
13. Pugliatti M., Riise T., Sotgiu M.A., Sotgiu S., Satta W.M., Mannu L., et al. Increasing incidence of multiple sclerosis in the province of Sassari, northern Sardinia. Neuroepidemiology 25 (2005) 129-134
14. Sloka J.S., Pryse-Phillips W.E., and Stefanelli M. Incidence and prevalence of multiple sclerosis in Newfoundland and Labrador. Can. J. Neurol. Sci. 32 (2005) 37-42
15. Orton S.M., Herrera B.M., Yee I.M., Valdar W., Ramagopalan S.V., Sadovnick A.D., et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol. 5 (2006) 932-936
16. Hader W.J., and Yee I.M. Incidence and prevalence of multiple sclerosis in Saskatoon, Saskatchewan. Neurology 69 (2007) 1224-1229
17. Debouverie M., Pittion-Vouyovitch S., Louis S., Roederer T., and Guillemin F. Increasing incidence of multiple sclerosis among women in Lorraine, Eastern France. Mult. Scler. 13 (2007) 962-967
18. Alonso A., and Hernan M.A. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 71 (2008) 129-135
19. Esbjerg S., Keiding N., and Koch-Henriksen N. Reporting delay and corrected incidence of multiple sclerosis. Stat. Med. 18 (1999) 1691-1706
20. Koch-Henriksen N., Bronnum-Hansen H., and Hyllested K. Incidence of multiple sclerosis in Denmark 1948-1982: a descriptive nationwide study. Neuroepidemiology 11 (1992) 1-10
21. Fasbender P., and Kolmel H.W. Incidence of multiple sclerosis in the urban area of Erfurt, Thuringia, Germany. Neuroepidemiology 30 (2008) 147-151
22. Midgard R., Riise T., Svanes C., Kvale G., and Nyland H. Incidence of multiple sclerosis in More and Romsdal, Norway from 1950 to 1991. An age-period-cohort analysis. Brain. 119 Pt 1 (1996) 203-211
23. Gronning M., Riise T., Kvale G., Nyland H., Larsen J.P., and Aarli J.A. Incidence of multiple sclerosis in Hordaland, western Norway: a fluctuating pattern. Neuroepidemiology 10 (1991) 53-61
24. Sumelahti M.L., Tienari P.J., Hakama M., and Wikstrom J. Multiple sclerosis in Finland: incidence trends and differences in relapsing remitting and primary progressive disease courses. J Neurol Neurosurg Psychiatry 74 (2003) 25-28
25. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13 (1983) 227-231
26. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50 (2001) 121-127
27. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
28. Kurtzke J.F. A new scale for evaluating disability in multiple sclerosis. Neurology 5 (1955) 580-583
29. Marrie R.A., Cutter G., Tyry T., Hadjimichael O., Campagnolo D., and Vollmer T. Changes in the ascertainment of multiple sclerosis. Neurology 65 (2005) 1066-1070
30. Marrie R.A., Horwitz R., Cutter G., Tyry T., Campagnolo D., and Vollmer T. Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology 72 (2009) 117-124
31. McDonnell G.V., and Hawkins S.A. Clinical study of primary progressive multiple sclerosis in Northern Ireland, UK. J. Neurol. Neurosurg. Psychiatry 64 (1998) 451-454
32. Wolinsky J.S. The diagnosis of primary progressive multiple sclerosis. J. Neurol. Sci. 206 (2003) 145-152
33. Miller D.H., and Leary S.M. Primary-progressive multiple sclerosis. Lancet Neurol. 6 (2007) 903-912
34. Sumelahti M.L., Tienari P.J., Wikstrom J., Salminen T.M., and Hakama M. Survival of multiple sclerosis in Finland between 1964 and 1993. Mult. Scler. 8 (2002) 350-355
35. Cottrell D.A., Kremenchutzky M., Rice G.P., Koopman W.J., Hader W., Baskerville J., et al. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 122 Pt 4 (1999) 625-639
36. Sorensen T.L., Frederiksen J.L., Bronnum-Hansen H., and Petersen H.C. Optic neuritis as onset manifestation of multiple sclerosis: a nationwide, long-term survey. Neurology 53 (1999) 473-478
37. Nicoletti A., Lo Bartolo M.L., Lo Fermo S., Cocuzza V., Panetta M.R., Marletta C., et al. Prevalence and incidence of multiple sclerosis in Catania, Sicily. Neurology 56 (2001) 62-66
38. Pugliatti M., Sotgiu S., Solinas G., Castiglia P., Pirastru M.I., Murgia B., et al. Multiple sclerosis epidemiology in Sardinia: evidence for a true increasing risk. Acta Neurol. Scand. 103 (2001) 20-26
39. Dahl O.P., Aarseth J.H., Myhr K.M., Nyland H., and Midgard R. Multiple sclerosis in Nord-Trondelag County, Norway: a prevalence and incidence study. Acta Neurol. Scand. 109 (2004) 378-384
40. Tremlett H., Paty D., and Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology 66 (2006) 172-177